Refractory Helicobacter pylori infection in Australia: updated multicentre antimicrobial resistance.
Helicobacter pylori
antibiotic
antimicrobial
antimicrobial resistance
levofloxacin
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
16
06
2023
accepted:
11
08
2023
medline:
27
11
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
ppublish
Résumé
Helicobacter pylori infection is responsible for considerable morbidity and mortality worldwide and eradication rates are falling globally because of increasing antimicrobial resistance. However, there is a paucity of local data to guide the choice of eradication therapy in Australia. This study aimed to evaluate current Australian rates of H. pylori antibiotic resistance in patients who had failed prior eradication therapy. A retrospective analysis of routine culture and antibiotic susceptibility data from two pathology laboratories servicing multiple tertiary referral hospitals in Western Australia (WA) and South Australia (SA), between 2018 and 2022, was performed. Rates of antimicrobial resistance and prevalence of multiresistant isolates in both SA and WA were calculated and comparison of temporal trends and differences between the two states was conducted. A total of 796 H. pylori isolates revealed a clarithromycin resistance rate of 82%, metronidazole 68%, amoxicillin 4.4% and tetracycline 0.5%. Resistance to levofloxacin was observed in 22% and rifampicin 14%. Rates of resistance to clarithromycin were lower in SA compared with WA (incidence rate ratio [IRR]: 0.69, P = 0.0001). Multiresistant isolates were discovered in 63% of patients, with lower rates in SA compared with WA (IRR: 0.74, P = 0.002). This first multicentre, multistate study of H. pylori resistance in Australian patients exposed to prior therapy demonstrated high rates of antimicrobial resistance, including levofloxacin (>20%). This raises concern about recommending levofloxacin in empirical second-line therapies. Increased monitoring and awareness of current H. pylori resistance rates in Australia are needed to guide local eradication practices.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Helicobacter pylori infection is responsible for considerable morbidity and mortality worldwide and eradication rates are falling globally because of increasing antimicrobial resistance. However, there is a paucity of local data to guide the choice of eradication therapy in Australia. This study aimed to evaluate current Australian rates of H. pylori antibiotic resistance in patients who had failed prior eradication therapy.
METHODS
METHODS
A retrospective analysis of routine culture and antibiotic susceptibility data from two pathology laboratories servicing multiple tertiary referral hospitals in Western Australia (WA) and South Australia (SA), between 2018 and 2022, was performed. Rates of antimicrobial resistance and prevalence of multiresistant isolates in both SA and WA were calculated and comparison of temporal trends and differences between the two states was conducted.
RESULTS
RESULTS
A total of 796 H. pylori isolates revealed a clarithromycin resistance rate of 82%, metronidazole 68%, amoxicillin 4.4% and tetracycline 0.5%. Resistance to levofloxacin was observed in 22% and rifampicin 14%. Rates of resistance to clarithromycin were lower in SA compared with WA (incidence rate ratio [IRR]: 0.69, P = 0.0001). Multiresistant isolates were discovered in 63% of patients, with lower rates in SA compared with WA (IRR: 0.74, P = 0.002).
CONCLUSION
CONCLUSIONS
This first multicentre, multistate study of H. pylori resistance in Australian patients exposed to prior therapy demonstrated high rates of antimicrobial resistance, including levofloxacin (>20%). This raises concern about recommending levofloxacin in empirical second-line therapies. Increased monitoring and awareness of current H. pylori resistance rates in Australia are needed to guide local eradication practices.
Substances chimiques
Anti-Bacterial Agents
0
Clarithromycin
H1250JIK0A
Levofloxacin
6GNT3Y5LMF
Amoxicillin
804826J2HU
Metronidazole
140QMO216E
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1972-1978Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020; 69: 2113-2121.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018; 155: 1372-1382.e17.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-533.
Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA et al. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: a systematic review and meta-analysis. J Gastroenterol Hepatol 2021; 36: 1450-1456.
Pateria P, Chin M, Goodheart R, McCullough C, Raby E, Robineron JO et al. Increasing secondary resistance to fluoroquinolones amongst Helicobacter pylori in Western Australia. Tasman Med J 2020; 2: 15-19.
Khan SF, Teng JC, Holmes JA, Perera C, Prendergast L, Waring L. Helicobacter pylori antimicrobial resistance in Melbourne, Australia. Time to review therapeutic guidelines? Intern Med J 2021; 51: 1919-1926.
Schubert JP, Warner MS, Rayner CK, Roberts-Thomson IC, Mangoni AA, Costello S et al. Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years. Intern Med J 2022; 52: 1554-1560.
Pan Y, Zheng Y, Yang J, Wei Y, Wu H, Liu S et al. A new biomarker for the early diagnosis of gastric cancer: gastric juice- and serum-derived SNCG. Future Oncol 2022; 18: 3179-3190.
Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia. Intern Med J 2017; 47: 761-766.
Therapeutic Guidelines. Helicobacter pylori infection Melbourne2016 (amended 2019). Available from URL: https://www.tg.org.au
Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis 2012; 18: 1453-1460.
Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2: 707-715.
Azrad M, Vazana D, On A, Paritski M, Rohana H, Roshrosh H et al. Antibiotic resistance patterns of Helicobacter pylori in North Israel - a six-year study. Helicobacter 2022; 27: e12932.
Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in primary antibiotic resistance in H. pylori strains isolated in Italy between 2009 and 2019. Antibiotics 2020; 9: 26.
Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW et al. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020; 13: 1756284820976990.
Sukri A, Lopes BS, Hanafiah A. The emergence of multidrug-resistant Helicobacter pylori in Southeast Asia: a systematic review on the trends and intervention strategies using antimicrobial peptides. Antibiotics 2021; 10: 1061.
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022; 71: 1724-1762.
Gisbert JP. Rifabutin for the treatment of Helicobacter Pylori infection: a review. Pathogens 2020; 10: 15.
Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol 2020; 15: 1185-1196.
Yang T, Liu B, Zhou J, Shen Y, Song X, Tang X et al. The inappropriateness of using rifampicin E-test to predict rifabutin resistance in Helicobacter pylori. J Infect Dis 2022; 226: S479-S485.
Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W et al. Effectiveness and safety of Pylera® in patients infected by Helicobacter pylori: a multicenter, retrospective, real life study. Dig Dis 2018; 36: 264-268.
Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021; 18: 613-629.
Kouhsari E, Sadeghifard N, Khadiv A, Sayadi H, Amiriani T, Ghafourian S et al. Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2022; 21: 19.
Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A et al. Helicobacter pylori heteroresistance to clarithromycin in adults - new data by in situ detection and improved concept. Helicobacter 2020; 25: e12670.
Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol 2019; 17: 479-496.
Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci 2014; 1: 19.
Australian Bureau of Statistics. Australia's population by country of birth; 2022.
Schubert JP, Woodman RJ, Mangoni AA, Rayner CK, Warner MS, Roberts-Thomson IC et al. Geospatial analysis of Helicobacter pylori infection in South Australia: should location influence eradication therapy? J Gastroenterol Hepatol 2022; 37: 1263-1274.
Bell JM, Lubian AF, Partridge SR, Gottlieb T, Iredell J, Daley DA et al. Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GnSOP) annual report 2020. Commun Dis Intell. 2022; 46. doi:10.33321/cdi.2022.46.11
Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D et al. A novel stool PCR test for Helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate. J Clin Microbiol 2017; 55: 2400-2405.
Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23: 2854-2869.